← Back to Screener
Avalo Therapeutics, Inc. Common Stock (AVTX)
Price$14.42
Favorite Metrics
Price vs S&P 500 (26W)-10.10%
Price vs S&P 500 (4W)-14.88%
Market Capitalization$328.61M
All Metrics
Book Value / Share (Quarterly)$4.49
P/TBV (Annual)8.32x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-85.16%
Cash Flow / Share (Quarterly)$-2.78
Price vs S&P 500 (YTD)-29.13%
Gross Margin (TTM)242.18%
Net Profit Margin (TTM)-23254.24%
EPS (TTM)$-6.04
10-Day Avg Trading Volume0.87M
EPS Excl Extra (TTM)$-6.04
Revenue Growth (5Y)-61.19%
EPS (Annual)$-5.84
ROI (Annual)-91.66%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-28808.20%
Cash / Share (Quarterly)$5.31
Revenue Growth QoQ (YoY)-69.27%
ROA (Last FY)-67.20%
Revenue Growth TTM (YoY)-86.62%
EBITD / Share (TTM)$-5.25
ROE (5Y Avg)-235.33%
Operating Margin (TTM)-33461.02%
Cash Flow / Share (Annual)$-2.78
P/B Ratio3.96x
P/B Ratio (Quarterly)3.97x
Net Income / Employee (Annual)$-3
EV / Revenue (TTM)5340.31x
Net Interest Coverage (TTM)-14.11x
ROA (TTM)-61.67%
EPS Incl Extra (Annual)$-5.84
Current Ratio (Annual)8.14x
Quick Ratio (Quarterly)7.60x
3-Month Avg Trading Volume0.54M
52-Week Price Return148.14%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.67
P/S Ratio (Annual)5569.65x
Asset Turnover (Annual)0.00x
52-Week High$20.72
Operating Margin (5Y Avg)-28457.44%
EPS Excl Extra (Annual)$-5.84
26-Week Price Return-6.12%
Quick Ratio (Annual)7.60x
13-Week Price Return-19.92%
Total Debt / Equity (Annual)0.03x
Current Ratio (Quarterly)8.14x
Enterprise Value$315.079
Revenue / Share Growth (5Y)-67.45%
Asset Turnover (TTM)0.00x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)128.40x
Pretax Margin (Annual)-132362.71%
Cash / Share (Annual)$5.31
3-Month Return Std Dev75.63%
Gross Margin (5Y Avg)93.93%
Net Income / Employee (TTM)$-3
ROE (Last FY)-94.23%
Net Interest Coverage (Annual)-3.00x
EPS Basic Excl Extra (Annual)$-5.84
Receivables Turnover (TTM)58.52x
Total Debt / Equity (Quarterly)0.03x
EPS Incl Extra (TTM)$-6.04
Receivables Turnover (Annual)34.06x
ROI (TTM)-76.00%
P/S Ratio (TTM)5569.65x
Pretax Margin (5Y Avg)-28747.55%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.45
Price vs S&P 500 (52W)118.31%
Year-to-Date Return-26.49%
5-Day Price Return-6.05%
EPS Normalized (Annual)$-5.84
ROA (5Y Avg)-94.16%
Net Profit Margin (Annual)-132642.37%
Month-to-Date Return-10.58%
Cash Flow / Share (TTM)$-1.61
EBITD / Share (Annual)$-5.41
Operating Margin (Annual)-123601.69%
LT Debt / Equity (Annual)0.02x
ROI (5Y Avg)-173.22%
LT Debt / Equity (Quarterly)0.02x
EPS Basic Excl Extra (TTM)$-6.04
P/TBV (Quarterly)12.89x
P/B Ratio (Annual)3.97x
Inventory Turnover (TTM)128.90x
Pretax Margin (TTM)-23033.90%
Book Value / Share (Annual)$4.49
Price vs S&P 500 (13W)-20.60%
Beta0.80x
P/FCF (Annual)26.16x
Revenue / Share (TTM)$0.00
ROE (TTM)-77.76%
52-Week Low$3.39
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.31
4.31
4.35
4.35
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
AVTXAvalo Therapeutics, Inc. Common Stock | 5569.65x | -86.62% | 242.18% | — | $14.42 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Avalo Therapeutics is a clinical-stage biotechnology company developing monoclonal antibodies and fusion proteins to treat immune dysregulation disorders. The company's lead asset, AVTX-009, is an anti-IL-1B monoclonal antibody targeting inflammatory diseases. Additional pipeline candidates include quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).